Home
Conditions
HCC - Hepatocellular Carcinoma

Clinical trial condition

HCC - Hepatocellular Carcinoma

Explore clinical trials studying HCC - Hepatocellular Carcinoma. Study availability and eligibility vary by location and protocol.

72 public trials 29 recruiting studies

Refine in advanced search Browse all conditions

HCC - Hepatocellular Carcinoma trial results

Enrolling by Invitation

Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals

NCT07088081

Conditions: Adenocarcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma, Carcinoma, +14 more
Locations: Ain Shams University Cairo, Abbasya, Egypt

View Trial Details

Not Yet Recruiting

Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome

NCT07691645

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +13 more
Locations: Zhejiang Cancer Hospital Hangzhou, Zhejiang, China

View Trial Details

Not Yet Recruiting

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT07687914

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma

NCT07668570

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

NCT07557914

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +15 more
Locations: The First Hospital of China Medical University Shenyang, Liaoning, China

View Trial Details

Not Yet Recruiting

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

NCT07618546

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Defining the Ablative Dose for Y-90 TARE

NCT07586046

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
Locations: Northwestern University Chicago, Illinois, United States

View Trial Details

Not Yet Recruiting

The DoHAICs Study Expansion Phase

NCT07584018

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Social Determinants of Health HCC Trial

NCT07568457

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Keck Hospital of USC Los Angeles, California, United States

LA General Medical Center Los Angeles, California, United States

USC Norris Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Not Yet Recruiting

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

NCT07535840

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
Locations: Not specified

View Trial Details

HCC - Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma trial results

Related conditions